Back to Authors

Schmitz, Christopher

0009-0008-2819-5918

Mayo Clinic

Department of Biochemistry and Molecular Biology (M.O.C., C.S., L.L.), Mayo Clinic, Rochester, MN.

Citations 4

Functional validation of a novel AAAS variant in an atypical presentation of Allgrove syndrome
Macke, Erica L. , Morales‐Rosado, Joel A. , Macklin‐Mantia, Sarah K. , Schmitz, Christopher T., Oskarsson, Björn , Klee, Eric W. , Wierenga, Klaas J. , Oskarsson, Björn , Schmitz, Christopher , Morales-Rosado, Joel A

Molecular Genetics & Genomic Medicine | May 16, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/mgg3.1966 Get It

AbstractBackgroundAchalasia‐addisonianism‐alacrima syndrome, frequently referred to as Allgrove syndrome or Triple A syndrome, is a multisystem disorder resulting from homozygous or compound heterozygous pathogenic variants in the gene encoding aladin (AAAS). Aladin is a member of the WD‐repeat family of proteins and is a component of the nuclear pore complex. It is thought to be involved in nuclear import and export of molecules. Here, we describe an individual with a paternally inherited truncating variant and a maternally inherited, novel missense variant in AAAS presenting with alacrima, achalasia, anejaculation, optic atrophy, muscle weakness, dysarthria, and autonomic dysfunction.MethodsWhole‐exome sequencing was performed in the proband, sister, and parents. Variants were confirmed by Sanger sequencing. The localization of aladin to the nuclear pore was assessed in cells expressing the patient variant.ResultsFunctional testing of the maternally inherited variant, p.(Arg270Pro), demonstrated decreased localization of aladin to the nuclear pore in cells expressing the variant, indicating a deleterious effect. Follow‐up testing in the proband's affected sister revealed that she also inherited the biallelic AAAS variants.ConclusionsReview of the patient's clinical, pathological, and genetic findings resulted in a diagnosis of Triple A syndrome.
Haploinsufficiency as a disease mechanism in GNB1 ‐associated neurodevelopmental disorder
Schultz‐Rogers, Laura , Masuho, Ikuo , Schmitz, Christopher T., Schwab, Tanya L., Gunderson, Lauren, Pichurin, Pavel N. , Wierenga, Klaas J. , Martemyanov, Kirill A. , Klee, Eric W. , Pinto E Vairo, Filippo, Wierenga, Klaas, Klee, Eric W , Schmitz, Christopher , Vairo, Filippo Pinto e , Clark, Karl J.

Molecular Genetics & Genomic Medicine | September 14, 2020 | Volume: 8 | Issue: 11 | Pages: No page available

10.1002/mgg3.1477 Get It

Abstract Background GNB1 encodes a subunit of a heterotrimeric G‐protein complex that transduces intracellular signaling cascades. Disruptions to the gene have previously been shown to be embryonic lethal in knockout mice and to cause complex neurodevelopmental disorders in humans. To date, the majority of variants associated with disease in humans have been missense variants in exons 5‐7. Methods Genetic sequencing was performed on two patients presenting with complex neurological phenotypes including intellectual disability, hypotonia, and in one patient seizures. Reported variants were assessed using RNA sequencing and functional BRET/BiFC assays. Results A splice variant reported in patient 1 was confirmed to cause usage of a cryptic splice site leading to a truncated protein product. Patient 2 was reported to have a truncating variant. BRET and BiFC assays of both patient variants confirmed both were deficient in inducing GPCR‐induced G protein activation due to lack of dimer formation with the Gγ subunit. Conclusion Here, we report two patients with functionally confirmed loss of function variants in GNB1 and neurodevelopmental phenotypes including intellectual disability, hypotonia, and seizures in one patient. These results suggest haploinsufficiency of GNB1 is a mechanism for neurodevelopmental disorders in humans.
Cortical phosphorylated α‐Synuclein levels correlate with brain wave spectra in Parkinson's disease
Caviness, John N., Lue, Lih‐Fen , Hentz, Joseph G. , Schmitz, Christopher T., Shill, Holly A. , Beach, Thomas G. , Walker, Douglas G. , Adler, Charles H. , Sabbagh, Marwan Noel , Schmitz, Christopher

Movement Disorders | April 10, 2016 | Volume: 31 | Issue: 7 | Pages: 1012-1019

10.1002/mds.26621 Get It

ABSTRACTIntroductionQuantitative EEG features have been identified as surrogates and predictors of cognitive decline/dementia, a common feature of progressive PD. The biochemical correlates for altered quantitative EEG features are unknown. Our primary objective was to test the hypothesis that quantitative EEG measures correlate with cortical levels of phosphorylated α‐synuclein, a modified form of the synaptic protein α‐synuclein, in PD cases, in contrast to other pathology‐associated proteins. A secondary objective was to explore the same correlations among cellular fractions of these proteins.MethodsWe used posterior cingulate cortex autopsy tissue from 44 PD subjects with various degrees of cognitive decline, who had undergone EEG. In this brain region, which is a major hub of the default mode network, biochemical measurements for levels of phosphorylated α‐synuclein, unmodified α‐synuclein, amyloid beta peptide, phosphorylated tau, and key synaptic proteins were analyzed and data correlated with spectral EEG measures.ResultsFindings revealed significant correlations between background rhythm peak frequency and all bandpower values (highest in delta bandpower) with total phosphorylated α‐synuclein, but not any correlation with total α‐synuclein, phosphorylated tau protein, amyloid beta peptide, or synaptic proteins. Certain fractions of synaptosomal‐associated protein 25 showed correlation with some quantitative EEG measures.ConclusionsThese data show an association between increased phosphorylation of α‐synuclein and the abnormal EEG signatures of cognitive decline. Results suggest that quantitative EEG may provide an in vivo approximation of phosphorylated α‐synuclein in PD cortex. This adds to previous evidence that quantitative EEG measures can be considered valid biomarkers of PD cognitive decline. © 2016 International Parkinson and Movement Disorder Society